- 67.2k views
Dapagliflozin in patients with Chronic Kidney Disease
Dapagliflozin is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor that has shown promise in the management of Chronic Kidney Disease (CKD) in patients with type 2 diabetes. Dapagliflozin has demonstrated efficacy in reducing the progression of CKD in individuals with type 2 diabetes by inhibiting the reabsorption of glucose and sodium in the proximal renal tubules. Clinical trials have indicated that dapagliflozin reduces albuminuria, a key marker of kidney damage, thereby potentially slowing the decline in renal function. The use of dapagliflozin has been associated with improvements in glomerular filtration rate (GFR), suggesting a positive impact on overall kidney function. Dapagliflozin's mechanism of action involves promoting glycosuria and natriuresis, leading to a reduction in intraglomerular pressure and ultimately protecting the kidneys. Studies have highlighted the cardiovascular benefits of dapagliflozin in CKD patients, including a reduction in major adverse cardiovascular events and heart failure hospitalizations. Dapagliflozin's renal protective effects extend beyond glycemic control, making it a valuable therapeutic option for patients with both diabetes and CKD. The safety profile of dapagliflozin in CKD patients appears favorable, with few adverse effects reported in clinical trials. Dapagliflozin's impact on renal outcomes has prompted its inclusion in treatment guidelines for individuals with type 2 diabetes and CKD.
About the Speaker
Dr Satyanarayana Garre
Consultant Nephrologist, Apollo Hospitals, Hyderabad
Upcoming Case Discussions
Technology Integration with Healthcare
Technology integration in healthcare is transforming the way medical services are delivered, enhancing efficiency and patient outcomes. Innovations such as telemedicine, electronic health records (EHR), and wearable devices allow for real-time monitoring and improved accessibility. Artificial intelligence (AI) and machine learning aid in early diagnosis and personalized treatment plans. Robotic surgeries and advanced imaging techniques offer precision and reduced recovery times. By combining technology with healthcare, providers can streamline operations, improve patient engagement, and deliver cost-effective care solutions.
Pediatric Obesity: Treatment Management
Treatment management for pediatric obesity combines lifestyle changes, family support, and, in severe cases, medical interventions. Family-based strategies are key, encouraging healthy eating habits, regular physical activity, and reduced screen time. Behavioral therapy helps set achievable goals and address barriers, empowering children and families to make sustainable lifestyle adjustments. Dietitians often assist in designing individualized meal plans that focus on nutrient-rich foods and limit calorie-dense options. In cases of severe obesity with related health conditions, medications or surgery may be considered, particularly for adolescents. Continuous monitoring and support from healthcare providers are essential for long-term success and health improvement.
Clinician’s Approach to Sleep Apnea
A clinician's approach to sleep apnea begins with a thorough assessment of the patient's medical history, symptoms (such as snoring, choking, and daytime fatigue), and risk factors like obesity or hypertension. Diagnosis is typically confirmed through polysomnography or home sleep apnea testing, followed by treatment strategies such as continuous positive airway pressure (CPAP), lifestyle modifications, or surgical interventions depending on the severity and type of sleep apnea.
Case Based Approach to Arthritis
A case-based approach to arthritis involves analyzing individual patient cases to tailor diagnostic and therapeutic strategies based on specific symptoms, disease progression, and underlying causes. This method enhances clinical decision-making by providing personalized treatment plans and improving patient outcomes in conditions like osteoarthritis, rheumatoid arthritis, and psoriatic arthritis.
Falls and Fractures in Older Adults: Prevention and Immediate Care
Falls and fractures in older adults are common and can lead to significant morbidity, highlighting the importance of fall prevention strategies such as strength training, balance exercises, and home safety modifications. Immediate care involves quick assessment for fractures, pain management, and stabilization, along with appropriate transport to healthcare facilities for further evaluation and treatment.
Author Post
Impact
+
Talks
+
webinar
+
no.of registrations
One liner about speaker
Why is speaker relevant?
Dr Satyanarayana Garre's Talks on Assimilate
- 1st-December-2023, TIME : 03:00PM - 04:00PM
- 0
Dapagliflozin is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor that has shown promise in the management of Chronic Kidney Disease (CKD) in patients with type 2 diabetes. Dapagliflozin has demonstrated efficacy in reducing the progression of CKD in individuals with type 2 diabetes by inhibiting the reabsorption of glucose and sodium in the proximal renal tubules. Clinical trials have indicated that dapagliflozin reduces albuminuria, a key marker of kidney damage, thereby potentially slowing the decline in renal function. The use of dapagliflozin has been associated with improvements in glomerular filtration rate (GFR), suggesting a positive impact on overall kidney function. Dapagliflozin's mechanism of action involves promoting glycosuria and natriuresis, leading to a reduction in intraglomerular pressure and ultimately protecting the kidneys. Studies have highlighted the cardiovascular benefits of dapagliflozin in CKD patients, including a reduction in major adverse cardiovascular events and heart failure hospitalizations. Dapagliflozin's renal protective effects extend beyond glycemic control, making it a valuable therapeutic option for patients with both diabetes and CKD. The safety profile of dapagliflozin in CKD patients appears favorable, with few adverse effects reported in clinical trials. Dapagliflozin's impact on renal outcomes has prompted its inclusion in treatment guidelines for individuals with type 2 diabetes and CKD.
- 1st-December-2023, TIME : 03:00PM - 04:00PM
- 0
Dapagliflozin is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor that has shown promise in the management of Chronic Kidney Disease (CKD) in patients with type 2 diabetes. Dapagliflozin has demonstrated efficacy in reducing the progression of CKD in individuals with type 2 diabetes by inhibiting the reabsorption of glucose and sodium in the proximal renal tubules. Clinical trials have indicated that dapagliflozin reduces albuminuria, a key marker of kidney damage, thereby potentially slowing the decline in renal function. The use of dapagliflozin has been associated with improvements in glomerular filtration rate (GFR), suggesting a positive impact on overall kidney function. Dapagliflozin's mechanism of action involves promoting glycosuria and natriuresis, leading to a reduction in intraglomerular pressure and ultimately protecting the kidneys. Studies have highlighted the cardiovascular benefits of dapagliflozin in CKD patients, including a reduction in major adverse cardiovascular events and heart failure hospitalizations. Dapagliflozin's renal protective effects extend beyond glycemic control, making it a valuable therapeutic option for patients with both diabetes and CKD. The safety profile of dapagliflozin in CKD patients appears favorable, with few adverse effects reported in clinical trials. Dapagliflozin's impact on renal outcomes has prompted its inclusion in treatment guidelines for individuals with type 2 diabetes and CKD.
- 1st-December-2023, TIME : 03:00PM - 04:00PM
- 0
Dapagliflozin is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor that has shown promise in the management of Chronic Kidney Disease (CKD) in patients with type 2 diabetes. Dapagliflozin has demonstrated efficacy in reducing the progression of CKD in individuals with type 2 diabetes by inhibiting the reabsorption of glucose and sodium in the proximal renal tubules. Clinical trials have indicated that dapagliflozin reduces albuminuria, a key marker of kidney damage, thereby potentially slowing the decline in renal function. The use of dapagliflozin has been associated with improvements in glomerular filtration rate (GFR), suggesting a positive impact on overall kidney function. Dapagliflozin's mechanism of action involves promoting glycosuria and natriuresis, leading to a reduction in intraglomerular pressure and ultimately protecting the kidneys. Studies have highlighted the cardiovascular benefits of dapagliflozin in CKD patients, including a reduction in major adverse cardiovascular events and heart failure hospitalizations. Dapagliflozin's renal protective effects extend beyond glycemic control, making it a valuable therapeutic option for patients with both diabetes and CKD. The safety profile of dapagliflozin in CKD patients appears favorable, with few adverse effects reported in clinical trials. Dapagliflozin's impact on renal outcomes has prompted its inclusion in treatment guidelines for individuals with type 2 diabetes and CKD.
- 1st-December-2023, TIME : 03:00PM - 04:00PM
- 0
Dapagliflozin is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor that has shown promise in the management of Chronic Kidney Disease (CKD) in patients with type 2 diabetes. Dapagliflozin has demonstrated efficacy in reducing the progression of CKD in individuals with type 2 diabetes by inhibiting the reabsorption of glucose and sodium in the proximal renal tubules. Clinical trials have indicated that dapagliflozin reduces albuminuria, a key marker of kidney damage, thereby potentially slowing the decline in renal function. The use of dapagliflozin has been associated with improvements in glomerular filtration rate (GFR), suggesting a positive impact on overall kidney function. Dapagliflozin's mechanism of action involves promoting glycosuria and natriuresis, leading to a reduction in intraglomerular pressure and ultimately protecting the kidneys. Studies have highlighted the cardiovascular benefits of dapagliflozin in CKD patients, including a reduction in major adverse cardiovascular events and heart failure hospitalizations. Dapagliflozin's renal protective effects extend beyond glycemic control, making it a valuable therapeutic option for patients with both diabetes and CKD. The safety profile of dapagliflozin in CKD patients appears favorable, with few adverse effects reported in clinical trials. Dapagliflozin's impact on renal outcomes has prompted its inclusion in treatment guidelines for individuals with type 2 diabetes and CKD.